Finnhub
BRISBANE - Vera Therapeutics, Inc. today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of...
Yahoo
BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new emplo
Yahoo
Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN). ORIGIN 3 follows the long-term results from the ORIGIN Phase 2b trial, which demonstrated sustained and substantial reductions in Gd-IgA1, hematuria, and proteinuria and showed stabilized kidney function through 96 weeks. The company anticipates the 36-week primary efficacy endpoint data from the
Yahoo
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial
SeekingAlpha
Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.
Yahoo
BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. The management team will also participate in on
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PPC | -0.03% | $12.65B | +69.08% | 0.00% |
VHC | 0.10% | $33.91M | +42.86% | 0.00% |
MKTX | -0.17% | $8.44B | +10.46% | 1.33% |
BG | 0.19% | $10.21B | -26.70% | 3.58% |
NUS | 0.21% | $293.49M | -51.63% | 4.02% |
GIS | -0.56% | $31.68B | -14.73% | 4.15% |
IMNN | -0.59% | $12.84M | -35.91% | 0.00% |
CME | 0.62% | $94.73B | +27.31% | 3.97% |
AGL | -0.68% | $2.28B | +23.44% | 0.00% |
STG | -0.68% | $24.92M | -41.66% | 0.00% |
NEUE | -0.69% | $55.48M | +8.46% | 0.00% |
CCEC | -0.76% | $1.03B | +6.20% | 3.40% |
CNC | -0.77% | $30.89B | -13.81% | 0.00% |
NEOG | 0.80% | $1.07B | -59.29% | 0.00% |
CPB | -0.82% | $11.25B | -12.30% | 4.03% |
BCE | 0.82% | $19.58B | -34.08% | 13.39% |
HLF | 0.87% | $663.85M | -20.10% | 0.00% |
AEP | 0.88% | $59.37B | +34.17% | 3.39% |
CL | 0.99% | $76.45B | +9.39% | 2.11% |
CBOE | 1.04% | $22.82B | +23.34% | 1.12% |
Current Value
$21.551 Year Return
Current Value
$21.551 Year Return
Double maintains 2 strategies that include VERA - Vera Therapeutics, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DNLI | 45.99% | $1.91B | -24.05% | 0.00% |
XNCR | 44.61% | $672.21M | -49.58% | 0.00% |
INFA | 43.71% | $5.32B | -49.77% | 0.00% |
PDFS | 43.27% | $701.31M | -43.85% | 0.00% |
ROIV | 43.17% | $7.18B | -6.07% | 0.00% |
CRNX | 42.98% | $2.76B | -31.80% | 0.00% |
BN | 41.67% | $73.94B | +27.43% | 0.67% |
XENE | 41.51% | $2.53B | -20.39% | 0.00% |
QTWO | 41.45% | $4.67B | +52.12% | 0.00% |
RGNX | 40.43% | $328.27M | -62.57% | 0.00% |
SXT | 40.30% | $3.17B | +9.43% | 2.19% |
BNT | 40.00% | $9.90B | +27.01% | 0.00% |
TROX | 39.92% | $831.93M | -67.35% | 9.48% |
ARWR | 39.85% | $1.77B | -45.63% | 0.00% |
NUVL | 39.82% | $5.07B | +9.31% | 0.00% |
CLDX | 39.65% | $1.22B | -52.41% | 0.00% |
IDYA | 39.27% | $1.49B | -58.76% | 0.00% |
TROW | 38.58% | $19.46B | -21.88% | 5.70% |
COGT | 38.47% | $554.45M | -24.61% | 0.00% |
VYGR | 38.46% | $177.21M | -59.77% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZ | 0.16% | $636.08M | 0.2% |
VTIP | -0.22% | $14.60B | 0.03% |
CANE | -0.33% | $10.43M | 0.29% |
DBE | -0.36% | $49.40M | 0.77% |
BILZ | -0.37% | $812.20M | 0.14% |
VGSH | 0.39% | $22.78B | 0.03% |
SCHO | -0.48% | $10.93B | 0.03% |
JPLD | -0.50% | $1.16B | 0.24% |
UGA | -0.86% | $71.03M | 0.97% |
UTWO | -0.92% | $376.15M | 0.15% |
USFR | -0.92% | $18.73B | 0.15% |
SHV | 0.95% | $22.83B | 0.15% |
IBTP | -1.11% | $118.92M | 0.07% |
IEI | 1.18% | $16.20B | 0.15% |
STPZ | -1.27% | $445.12M | 0.2% |
VGIT | 1.46% | $31.42B | 0.04% |
IBTI | 1.54% | $982.50M | 0.07% |
TBLL | -1.71% | $2.55B | 0.08% |
JPST | 1.82% | $29.69B | 0.18% |
GOVZ | 1.84% | $256.78M | 0.1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 53.38% | $4.93B | 0.35% |
IBB | 47.77% | $5.38B | 0.45% |
IWO | 46.00% | $10.38B | 0.24% |
XT | 45.98% | $2.88B | 0.46% |
GNOM | 45.45% | $46.95M | 0.5% |
CLOU | 45.44% | $302.59M | 0.68% |
KJUL | 45.19% | $119.66M | 0.79% |
PBE | 45.11% | $215.10M | 0.58% |
KAPR | 45.01% | $165.62M | 0.79% |
BOTZ | 44.86% | $2.21B | 0.68% |
KOMP | 44.53% | $1.91B | 0.2% |
ROBO | 44.40% | $856.25M | 0.95% |
AOR | 44.35% | $2.25B | 0.15% |
VT | 44.29% | $40.76B | 0.06% |
SPGM | 44.17% | $927.00M | 0.09% |
DFAW | 44.06% | $621.00M | 0.25% |
ISCG | 44.01% | $615.25M | 0.06% |
ROBT | 44.00% | $397.50M | 0.65% |
VBK | 44.00% | $16.36B | 0.07% |
RYLD | 43.99% | $1.28B | 0.6% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -17.31% | $32.73M | -63.11% | 0.00% |
FMTO | -15.13% | $328.20K | -99.76% | 0.00% |
VRCA | -5.48% | $45.28M | -92.95% | 0.00% |
DOGZ | -5.34% | $245.83M | +187.35% | 0.00% |
HUSA | -5.11% | $8.86M | -70.43% | 0.00% |
CORT | -5.11% | $7.34B | +197.52% | 0.00% |
CYD | -5.10% | $684.38M | +100.60% | 2.27% |
WBA | -4.77% | $9.38B | -38.49% | 6.92% |
ED | -3.71% | $40.27B | +27.90% | 2.98% |
SYPR | -3.62% | $40.98M | +4.71% | 0.00% |
KR | -3.56% | $45.03B | +23.26% | 1.83% |
EXC | -3.11% | $47.19B | +30.74% | 3.29% |
AGS | -2.64% | $491.80M | +30.85% | 0.00% |
VSA | -2.62% | $4.33M | -77.89% | 0.00% |
BNED | -2.31% | $318.74M | -62.56% | 0.00% |
K | -1.79% | $28.41B | +48.26% | 2.76% |
CVS | -1.68% | $87.00B | -0.16% | 3.87% |
PRT | -1.07% | $45.01M | -9.54% | 12.14% |
CPB | -0.82% | $11.25B | -12.30% | 4.03% |
CNC | -0.77% | $30.89B | -13.81% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -31.86% | $98.14M | 0.59% |
VIXY | -29.69% | $195.31M | 0.85% |
BTAL | -29.40% | $407.58M | 1.43% |
KCCA | -12.77% | $93.98M | 0.87% |
USDU | -12.11% | $214.66M | 0.5% |
FTSD | -10.61% | $219.54M | 0.25% |
WEAT | -10.38% | $122.71M | 0.28% |
UUP | -9.53% | $253.11M | 0.77% |
IVOL | -8.18% | $351.97M | 1.02% |
TFLO | -8.03% | $7.07B | 0.15% |
GBIL | -6.96% | $6.31B | 0.12% |
XONE | -6.09% | $626.68M | 0.03% |
KRBN | -5.98% | $152.32M | 0.85% |
ULST | -5.79% | $624.58M | 0.2% |
BIL | -5.23% | $48.53B | 0.1356% |
TPMN | -4.86% | $31.08M | 0.65% |
UNG | -4.04% | $373.14M | 1.06% |
BUXX | -3.64% | $260.49M | 0.25% |
CARY | -3.49% | $347.36M | 0.8% |
SHYM | -3.33% | $300.97M | 0.35% |